1. 422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts. (9th November 2020) Authors: Middleton, Mark; Aroldi, Francesca; Sacco, Joseph; Milhem, Mohammed; Curti, Brendan; MBioeth, Ari VanderWalde; Baum, Scott; Samson, Adel; Pavlick, Anna; Chesney, Jason; Niu, Jiaxin; Rhodes, Terence; Bowles, Tawnya; Conry, Robert; Olsson-Brown, Anna; Laux, Douglas Earl; Kaufman, Howard; Bommareddy... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗